Quarterly Results Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Mar'26
Dec'25
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Net Sales
905.39
217.04
217.79
208.01
167.64
148.84
143.42
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
905.39
217.04
217.79
208.01
167.64
148.84
143.42
Raw Material Cost
27.04
30.88
28.31
31.70
31.82
23.32
22.88
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
6.00
6.97
3.35
6.67
7.21
7.10
6.45
Selling and Distribution Expenses
153.16
155.77
124.73
138.44
104.48
93.82
78.47
Other Expenses
8.63
11.37
9.65
7.96
8.71
10.05
7.75
Total Expenditure (Excl Depreciation)
272.49
307.36
252.89
256.44
230.56
224.71
185.35
Operating Profit (PBDIT) excl Other Income
632.9
-90.3
-35.099999999999994
-48.4
-62.9
-75.9
-41.900000000000006
Other Income
7.18
28.24
19.91
14.54
40.56
41.09
15.28
Operating Profit (PBDIT)
637.21
-49.95
-4.99
-26.03
-8.71
-18.68
-10.27
Interest
6.00
6.97
3.35
6.67
7.21
7.10
6.45
Exceptional Items
0.55
-0.00
0.84
0.00
0.00
0.02
0.29
Gross Profit (PBDT)
878.35
186.17
189.47
176.30
135.82
125.52
120.54
Depreciation
0.00
13.40
13.40
14.40
14.40
16.68
16.68
Profit Before Tax
631.77
-70.34
-20.90
-47.10
-30.32
-42.45
-33.11
Tax
-0.84
-0.81
-0.88
-0.84
-1.00
-1.79
-0.99
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
632.61
-69.53
-20.61
-44.54
-28.26
-39.93
-31.37
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
632.61
-69.53
-20.61
-44.54
-28.26
-39.93
-31.37
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.59
-1.72
-1.05
-0.72
-0.75
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
632.61
-69.53
-20.03
-46.26
-29.31
-40.65
-32.12
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
1,713.05
1,080.45
1,149.01
1,176.62
1,226.01
1,253.86
1,303.39
Earnings per share (EPS)
2.39
-0.26
-0.08
-0.17
-0.11
-0.15
-0.12
Diluted Earnings per share
2.39
-0.26
-0.08
-0.17
-0.11
-0.15
-0.12
Operating Profit Margin (Excl OI)
69.59%
-42.2%
-17.59%
-26.43%
-37.98%
-51.37%
-29.45%
Gross Profit Margin
69.78%
-26.23%
-3.44%
-15.72%
-9.49%
-17.31%
-11.45%
PAT Margin
69.87%
-32.03%
-9.46%
-21.41%
-16.86%
-26.83%
-21.87%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
Net Sales
YoY Growth in quarter ended Mar 2026 is 440.21% vs 54.90% in Mar 2025
Consolidate Net Profit
YoY Growth in quarter ended Mar 2026 is 2,259.04% vs 34.30% in Mar 2025
Operating Profit (PBDIT) excl Other Income
YoY Growth in quarter ended Mar 2026 is 1,377.89% vs -11.54% in Mar 2025
Interest
YoY Growth in quarter ended Mar 2026 is -16.67% vs 2.86% in Mar 2025
Operating Profit Margin (Excl OI)
YoY Growth in quarter ended Mar 2026 has improved from Mar 2025
Compare Quarterly Results Of Suzhou Zelgen Biopharmaceuticals Co., Ltd. With
Figures in Million
Consolidate Quarterly Results
Change(CNY)
Change(%)
Net Sales
905.39
0
905.39
Other Operating Income
0.00
0.00
0.00
Total Operating income
905.39
0
905.39
Raw Material Cost
27.04
0
27.04
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
6.00
0
6.00
Selling and Distribution Expenses
153.16
0
153.16
Other Expenses
8.63
0.00
8.63
Total Expenditure (Excl Depreciation)
272.49
0
272.49
Operating Profit (PBDIT) excl Other Income
632.91
0.00
632.91
Other Income
7.18
0
7.18
Operating Profit (PBDIT)
637.21
0
637.21
Interest
6.00
0
6.00
Exceptional Items
0.55
0
0.55
Gross Profit (PBDT)
878.35
0
878.35
Depreciation
0.00
0
0.00
Profit Before Tax
631.77
0
631.77
Tax
-0.84
0
-0.84
Provisions and contingencies
0
0
0.00
Profit After Tax
632.61
0
632.61
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
632.61
0
632.61
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
632.61
0
632.61
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
1,713.05
0
1,713.05
Earnings per share (EPS)
2.39
0
2.39
Diluted Earnings per share
2.39
0
2.39
Operating Profit Margin (Excl OI)
69.59%
0%
0.00
69.59%
Gross Profit Margin
69.78%
0%
0.00
69.78%
PAT Margin
69.87%
0%
0.00
69.87%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 90.54 Million
in Mar 2026Figures in Million
QoQ Growth in quarter ended Mar 2026 is 317.24% vs -0.37% in Dec 2025
YoY Growth in quarter ended Mar 2026 is 440.21% vs 54.90% in Mar 2025
Quarterly - Consolidate Net Profit
Consolidate Net Profit 63.26 Million
in Mar 2026Figures in Million
QoQ Growth in quarter ended Mar 2026 is 1,010.22% vs -247.50% in Dec 2025
YoY Growth in quarter ended Mar 2026 is 2,259.04% vs 34.30% in Mar 2025
Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 63.00 Million
in Mar 2026Figures in Million
QoQ Growth in quarter ended Mar 2026 is 905.63% vs -214.06% in Dec 2025
YoY Growth in quarter ended Mar 2026 is 1,377.89% vs -11.54% in Mar 2025
Quarterly - Interest
Interest 0.60 Million
in Mar 2026Figures in Million
QoQ Growth in quarter ended Mar 2026 is -14.29% vs 105.88% in Dec 2025
YoY Growth in quarter ended Mar 2026 is -16.67% vs 2.86% in Mar 2025
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 69.59%
in Mar 2026Figures in %
QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025
YoY Growth in quarter ended Mar 2026 has improved from Mar 2025
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
